Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related ...

Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

Ozempic, Mounjaro and other weight loss drugs can have nasty side effects, and reducing the volume of food you eat will also ...

Danish pharmaceutical company Novo Nordisk announced last weekend that Wegovy, the weight-loss version of the company's ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The Ipsos survey of 1,078 adults found 24 of people would use weight-loss jabs if they were provided for free by the health service.

Ozempic, Wegovy and Mounjaro are often the most popular weight loss drugs. While these medications help people lose weight, they have undesirable side effects. Now, scientists at the University of ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...